



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
T. Van Meerhaeghe
✉ tess.van.meerhaeghe@
erasme.ulb.ac.be

SPECIALTY SECTION
This article was submitted to
Onconeurology,
a section of the journal
Frontiers in Nephrology

RECEIVED 21 December 2022
ACCEPTED 22 December 2022
PUBLISHED 05 January 2023

CITATION
Van Meerhaeghe T, Baurain JF,
Bechter O, Orte Cano C, Del
Marmol V, Devresse A, Doubel P,
Hanssens M, Hellemans R, Lienard D,
Rutten A, Sprangers B, Le Moine A and
Aspeslagh S (2023) Corrigendum:
Cemiplimab for advanced cutaneous
squamous cell carcinoma in kidney
transplant recipients.
Front. Nephrol. 2:1129134.
doi: 10.3389/fneph.2022.1129134

COPYRIGHT
© 2023 Van Meerhaeghe, Baurain,
Bechter, Orte Cano, Del Marmol,
Devresse, Doubel, Hanssens, Hellemans,
Lienard, Rutten, Sprangers, Le Moine
and Aspeslagh. This is an open-access
article distributed under the terms of
the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution
or reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

T. Van Meerhaeghe^{1*}, J.F. Baurain², O. Bechter³,
C. Orte Cano⁴, V. Del Marmol⁴, A. Devresse⁵, P. Doubel⁶,
M. Hanssens⁷, R. Hellemans⁸, D. Lienard⁴, A. Rutten⁹,
B. Sprangers¹⁰, A. Le Moine¹ and S. Aspeslagh¹¹

¹Department of Nephrology, Hôpital Erasme – Université Libre de Bruxelles (ULB), Brussels, Belgium, ²Department of Oncology, Clinique Universitaire Saint-Luc – Université Catholique de Louvain (UCLouvain), Brussels, Belgium, ³Department of Oncology, Universitair Ziekenhuis (UZ) Leuven – Katholieke Universiteit Leuven (KUL), Leuven, Belgium, ⁴Department of Dermatology, Hôpital Erasme – Université Libre de Bruxelles (ULB), Brussels, Belgium, ⁵Department of Nephrology, Clinique Universitaire Saint-Luc – Université Catholique de Louvain (UCLouvain), Brussels, Belgium, ⁶Department of Nephrology, Academisch Ziekenhuis (AZ) Groeninge, Kortrijk, Belgium, ⁷Department of Oncology, Academisch Ziekenhuis (AZ) Groeninge, Kortrijk, Belgium, ⁸Department of Nephrology, Universitair Ziekenhuis (UZ) Antwerpen, Antwerpen, Belgium, ⁹Department of Oncology, GasthuisZuster, Antwerpen, Belgium, ¹⁰Department of Nephrology, Universitair Ziekenhuis (UZ) Leuven – Katholieke Universiteit Leuven (KUL), Leuven, Belgium, ¹¹Department of Oncology, Universitair Ziekenhuis (UZ) Brussel – Vrije Universiteit Brussel (VUB), Brussels, Belgium

KEYWORDS

cemiplimab, kidney transplant recipients, cutaneous squamous cell carcinoma, immune checkpoint inhibitors, rejection

A corrigendum on

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

by Van Meerhaeghe T, Baurain JF, Bechter O, Orte Cano C, Del Marmol V, Devresse A, Doubel P, Hanssens M, Hellemans R, Lienard D, Rutten A, Sprangers B, Le Moine A and Aspeslagh S (2022) *Front. Nephrol.* 2:1041819. doi: 10.3389/fneph.2022.1041819

In the published article, there was a mistake in the **Funding** statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.

Funding

TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.